This Funding Opportunity Announcement (FOA) is intended to continue support for the Pediatric Brain Tumor Consortium (PBTC). This Limited-Competition FOA solicits a single application from the current PBTC awardee. The PBTC was conceived as a dedicated clinical trials organization able to translate innovative therapies from the laboratory to early phase clinical testing so that treatment for primary brain tumors in children can be improved. The importance of the PBTC is highlighted by the continuing high mortality rate among some common brain tumors occurring in children [e.g., diffuse intrinsic pontine gliomas (DIPG), malignant supratentorial gliomas, and biologically high-risk medulloblastomas and ependymomas] and the functional impediments apparent in a large proportion of children surviving current therapies. The PBTC is designed to fill a unique niche in the NIH pediatric brain tumor research portfolio through its ability to translate multiple innovative therapies from the laboratory to early phase clinical testing.
Brief Description